GlassScriptPhysician profile
Mindy C Hsiao
NPI 1083091912
$3,490.72
in general payments reported to CMS, 2019-2025
33 companies · $88.77 in 2025
The $88.77 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $429 · 2021: $226 · 2022: $184 · 2023: $935 · 2024: $1,112 · 2025: $88.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $453.80 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $268.09 | 2020-2023 | |
| Daiichi Sankyo INC. | $236.51 | 2023-2024 | Vanflyta |
| Celgene Corporation | $231.04 | 2020-2024 | Pomalyst, Reblozyl |
| Genmab U.S., INC. | $211.47 | 2023 | Epkinly |
| Abbvie INC. | $195.30 | 2020-2025 | |
| Pfizer INC. | $168.96 | 2019-2025 | |
| Genzyme Corporation | $158.25 | 2020-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $134.06 | 2022-2023 | Imbruvica |
| Incyte Corporation | $128.26 | 2019-2024 | Monjuvi |
| Tg Therapeutics, INC. | $125.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $122.57 | 2019-2024 | |
| Servier Pharmaceuticals LLC | $122.07 | 2022-2024 | |
| Glaxosmithkline, LLC. | $116.68 | 2020-2024 | Ojjaara |
| Astellas Pharma US INC | $111.17 | 2022-2024 | Xospata, Cresemba |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $86.12 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.61 | 2023-2024 | Iclusig |
| Adc Therapeutics America, INC. | $78.75 | 2024 | |
| Kite Pharma, INC. | $74.47 | 2024-2025 | Yescarta |
| Beigene USA, INC. | $59.87 | 2023-2024 | Brukinsa |
| Janssen Biotech, INC. | $43.83 | 2023-2025 | Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $38.83 | 2020 | |
| Rigel Pharmaceuticals, INC. | $35.70 | 2024 | Rezlidhia, Tavalisse |
| Eisai INC. | $24.90 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $24.77 | 2019 | |
| Epizyme, INC. | $24.53 | 2020 | |
| Alexion Pharmaceuticals, INC. | $23.45 | 2019 | |
| Pharmaessentia USA Corporation | $22.77 | 2024 | Besremi |
| Genentech USA, INC. | $20.17 | 2023 | Venclexta |
| Lilly USA, LLC | $19.15 | 2023 | Jaypirca |
| Sobi, INC | $17.25 | 2024 | |
| Secura Bio, INC. | $15.82 | 2024 | Copiktra |
| Seagen INC. | $13.50 | 2023 | Adcetris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mindy Hsiao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.